ferric pyrophosphate citrate
Trade name: Triferic
Small moleculeapproved
Approved
Jan 23, 2015
Iron(III) pyrophosphate is an inorganic chemical compound with the formula Fe4(P2O7)3. — Wikipedia
Clinical trial activity
30 trials · 20 clinical orgs · 1 marketing orgs
Phase 1
11
Phase 2
13
Phase 3
4
Phase 4
1
Earliest trial started Oct 1, 2003 (NCT00867867)
Timeline
2000s
- Jan 1, 2003
Earliest Phase 1 Sponsor(trial)
- Jan 1, 2007
Rockwell Medical Inc — Earliest Phase 2 Sponsor(trial)
2010s
- Jan 1, 2011
Rockwell Medical Inc — Earliest Phase 3 Sponsor(trial)
- Jan 23, 2015
Rockwell Medical Inc — Earliest FDA Approval
- Jan 23, 2015
Rockwell Medical Inc — NDA Secondary Org
- Jan 23, 2015
Rockwell Medical Inc — NDA Organization
Indications
Approved for
Mechanism of action
- Ferritin light chainBINDING AGENT
FTL binding agent
- Hemoglobin alpha subunitBINDING AGENT
Hemoglobin alpha subunit binding agent
- Unspecified targetOTHER
Supplement
Iron replacement product
Approval history
- approvedJan 23, 2015
Chemistry & pharmacology
- Mol. weight
- 1321.57 g/mol
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Discontinued
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaIron(III) pyrophosphate ↗
- ChEMBLCHEMBL4297752 ↗
- ChEMBLCHEMBL3833317 ↗
- ChEMBLCHEMBL3544987 ↗
Also known as
- actiferol fe
- ferric pyrophosphate
- ferric pyrophosphate
- ferric pyrophosphate
- ferric pyrophosphate
- ferric pyrophosphate
- ferric pyrophosphate citrate
- ferric pyrophosphate citrate
- ferric pyrophosphate citrate
- ferric pyrophosphate citrate
- ferric pyrophosphate soluble
- iron(iii) pyrophosphate
- iron(iii) pyrophosphate
- iron pyrophosphate
- iron pyrophosphate
- iron pyrophosphate
- sodium ferricitropyrophosphate
- soluble ferric pyrophosphate
- soluble ferric pyrophosphate
- soluble ferric pyrophosphate
- sunactive fe
- triferic
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05985070 | N/A | Jul 17, 2023 | Liaquat University of Medical & Health Sciences |
| NCT05110768 | Phase 2 | Nov 30, 2021 | Rockwell Medical Inc |
| NCT04689932 | Phase 4 | Apr 19, 2021 | Rockwell Medical Inc |
| NCT04409132 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2020 | Rockwell Medical Inc |
| NCT04239391 | Phase 3 | Jan 30, 2020 | Rockwell Medical Inc |
| NCT04042324 | Phase 1/Phase 2 (Phase 2) | Aug 20, 2019 | Rockwell Medical Inc |
| NCT03762148 | N/A | Mar 12, 2019 | Antistress AG, Swiss Federal Institute of Technology, University of Zurich |
| NCT03303144 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2017 | Orlando Clinical Research Center, Rockwell Medical Inc |
| NCT02909153 | Phase 1 | Jan 1, 2017 | Rockwell Medical Inc |
| NCT03586245 | N/A | Oct 28, 2016 | Iowa State University |
| NCT02905981 | Phase 2 | Oct 1, 2016 | Rockwell Medical Inc |
| NCT02714075 | N/A | Apr 30, 2016 | Swiss Federal Institute of Technology, University for Development Studies, Tamale, Ghana |
| NCT02767128 | Phase 1 | Apr 1, 2016 | Rockwell Medical Inc |
| NCT02739100 | Phase 1 | Apr 1, 2016 | Rockwell Medical Inc |
| NCT03771092 | N/A | Nov 2, 2015 | University of Palermo |
| NCT02595437 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2015 | Rockwell Medical Inc |
| NCT02636049 | Phase 1 | Oct 1, 2015 | Rockwell Medical Inc |
| NCT02255942 | N/A | Apr 30, 2015 | PATH, Swiss Federal Institute of Technology |
| NCT01991626 | N/A | Sep 1, 2013 | DSM, Swiss Federal Institute of Technology, University of Zurich |
| NCT01894906 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2013 | Rockwell Medical Inc |
Showing 20 of 30 trials
Page 1 / 2
Organizations
Research & Development (20)
20 organizations
Page 1 / 1
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Rockwell Medical Inc | For profit | NDA2 | Jan 23, 2015 |
| Rockwell Medical Inc | For profit | NDA | Jan 23, 2015 |